Αρχική World News Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with... World News Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma Από Ogkologos - 10 Σεπτεμβρίου, 2025 670 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Nirogacestat 3 Ιουλίου, 2025 Nivolumab Achieves High ORR and Durable PFS in Patients with dMMR/MSI-H... 3 Μαΐου, 2024 Study Says Exercise Combats Side Effects of Chemo and Other Meds... 7 Ιουλίου, 2021 Rare Disease Day: Raising Awareness for Rare Cancers 26 Φεβρουαρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Navigating the Challenges of Gynecologic Cancer Survivorship: An Expert Perspective Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting... ΤΙ ΕΙΝΑΙ Διαφημιστείτε